[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"orbital-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:orbital-lymphoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100609145","radiotherapy-12gy-in-6-fractions-for-orbital-lymphoma-100609145",false,"NCT07210749","Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma","A Phase II Trial Assessing 12 Gy in 6 Fractions Radiotherapy for Low-Grade B-cell Orbital Lymphoma","Inclusion Criteria:\n\n* Age ≥18 years with stage I-IV indolent NHL\\*\n* Able to provide informed consent\n* Histologically confirmed indolent NHL involving one or both orbits. If bilateral, biopsy of only one orbit is permitted as long as high clinical suspicion of contralateral orbit involvement\n* Measurable orbital disease after biopsy, either clinically or radiographically\n* ECOG performance status 0-3\n* Life expectancy \\>12 months\n* Available for treatment and follow-up (including scheduled post-treatment imaging and ophthalmologic exam)\n* Able and willing to complete quality of life questionnaires via paper or online portal if they provide their email address on the informed consent document\n\n  * Stage II-IV allowed but if systemic therapy given after RT the timing will be recorded, and subjects will be stratified according to receipt of systemic therapy\n\nExclusion Criteria:\n\n* Aggressive NHL histology (including grade 3B follicular lymphoma)\n* Prior RT to orbit\n* Patients requiring treatments outside standard clinical hours\n* Systemic therapy for lymphoma is not permitted within the period of time between 2 weeks prior to RT start and 2 weeks after RT completion\n* Patients who are pregnant\n* History of other malignancy within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death and\u002For treated with expected curative outcome (for example, appropriately treated non-melanoma skin cancer, carcinoma in-situ of the cervix, localized prostate cancer, breast ductal carcinoma in-situ, or stage I endometrial cancer)\n* Any medical condition that, in the investigator's judgement, would preclude the individual's safe participation in and completion of the study, or could affect interpretation of the results (e.g. pre-existing retinopathy, active connective tissue disease)\n* Inability to comply with study and follow-up procedures","ALL","18 Years",{"count":19,"type":20},36,"ESTIMATED","INTERVENTIONAL",[23],"NA","Current standard RT doses (24-25Gy) provide excellent disease control for patients with indolent B-cell orbital lymphoma, but can cause significant late toxicities. Ultra-low dose RT (4Gy in 2 fractions) has minimal toxicity but lower disease control, requiring intensive follow-up to salvage persistent tumors. Some centers are moving towards this dose as the new standard. A recent study using 12Gy in 4 fractions to any body site showed early data suggesting high disease control rates with minimal toxicity. This study assesses 12Gy in 6 fractions, aiming to enhance disease control over 4Gy while reducing toxicity compared to 24Gy.",[26],"Orbital Lymphoma","NOT_YET_RECRUITING","2025-10-02",{"date":30,"type":31},"2025-10-07","ACTUAL",{"date":33,"type":20},"2025-11-01",{"date":35,"type":20},"2036-08-31",{"name":37,"class":38},"British Columbia Cancer Agency","OTHER"]